Education
About Us
Working with TipRanks
Follow Us
Valneva (VALN)
NASDAQ:VALN
VALN Stock Chart & Stats
$8.72
$0.03(0.64%)
At close: 4:00 PM EST
$8.72
$0.03(0.64%)
Day’s Range― - ―
52-Week Range$3.62 - $12.25
Previous CloseN/A
Volume18.63K
Average Volume (3M)53.05K
Market Cap
$727.21M
Enterprise Value$502.21M
Total Cash (Recent Filing)$161.31M
Total Debt (Recent Filing)$196.92M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 13, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding85,979,140
10 Day Avg. Volume24,300
30 Day Avg. Volume53,054
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)1.64
Price to Sales (P/S)1.75
P/FCF Ratio-3.54
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit5.22
Enterprise Value/Ebitda-12.17
Forecast
1Y Price Target
$15.00Price Target Upside72.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial OpportunityThe VLA15 Lyme vaccine addresses a substantial unmet need and commercial opportunity as there are no approved vaccines for Lyme disease.
Partnership BenefitsValneva retains meaningful upside via royalties and milestone payments, with Pfizer covering all post-Phase 2 development and commercialization costs.
Vaccine DevelopmentThe largest value driver for VALN going forward remains VLA15, the company’s Phase 3 Lyme disease vaccine candidate being co-developed globally with Pfizer.
Bears Say
Development And Regulatory RisksKey risks include VLA15 development or regulatory delays, commercial execution risk for IXCHIQ and future launches, and the need for additional funding if milestone or royalty income falls short of projections.
FDA And Program UncertaintyThe stock pullback due to FDA ambiguity/program uncertainty for Ixchiq is justified.
Regulatory ChallengesThe FDA has suspended the license for IXCHIQ following four new reports of serious adverse events, requiring Valneva to halt all shipments and sales of IXCHIQ in the U.S.
Valneva News
VALN FAQ
What was Valneva’s price range in the past 12 months?
Valneva lowest stock price was $3.62 and its highest was $12.25 in the past 12 months.
What is Valneva’s market cap?
Valneva’s market cap is $727.21M.
When is Valneva’s upcoming earnings report date?
Valneva’s upcoming earnings report date is Nov 13, 2025 which is in 3 days.
How were Valneva’s earnings last quarter?
Valneva released its earnings results on Aug 12, 2025. The company reported -$0.162 earnings per share for the quarter, beating the consensus estimate of -$0.324 by $0.162.
Is Valneva overvalued?
According to Wall Street analysts Valneva’s price is currently Undervalued.
Does Valneva pay dividends?
Valneva does not currently pay dividends.
What is Valneva’s EPS estimate?
Valneva’s EPS estimate is -0.33.
How many shares outstanding does Valneva have?
Valneva has 85,979,140 shares outstanding.
What happened to Valneva’s price movement after its last earnings report?
Valneva reported an EPS of -$0.162 in its last earnings report, beating expectations of -$0.324. Following the earnings report the stock price went up 10.588%.
Which hedge fund is a major shareholder of Valneva?
Currently, no hedge funds are holding shares in VALN
Valneva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (72.02% Upside)
$15.00 (72.02% Upside)
Blogger Sentiment
Neutral
VALN Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.12%
12-Months-Change
Fundamentals
Return on Equity
-36.50%
Trailing 12-Months
Asset Growth
10.95%
Trailing 12-Months
Company Description
Valneva
Valneva SE is a biotechnology company focused on developing and commercializing innovative vaccines for infectious diseases. Headquartered in Lyon, France, Valneva operates in the pharmaceutical sector, with a particular emphasis on vaccine development for diseases such as Lyme disease, COVID-19, and chikungunya. The company's core products include its proprietary inactivated vaccine for Japanese encephalitis and a COVID-19 vaccine candidate, among others. Valneva's mission is to address unmet medical needs by leveraging its expertise in vaccine technology.
VALN Company Deck
VALN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth, strong cash position, and progress in vaccine development, suggesting a positive outlook. However, challenges include an operating loss and increased R&D expenses. The sentiment is balanced with a slight positive tilt due to strategic advances.View all VALN earnings summariesVALN Stock 12 Month Forecast
Average Price Target
$15.00
▲(72.02% Upside)
Technical Analysis
Arbutus Biopharma
―
Urogen Pharma
―
Inventiva
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Ownership Overview
―
Insiders
0.14% Mutual Funds
4.92% Other Institutional Investors
94.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---